
Diego Arango

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8595210/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Histone Deacetylase 3 (HDAC3) and Other Class I HDACs Regulate Colon Cell Maturation and p21 Expression and Are Deregulated in Human Colon Cancer. Journal of Biological Chemistry, 2006, 281, 13548-13558.	3.4	486
2	PIK3CA Mutation/PTEN Expression Status Predicts Response of Colon Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Cetuximab. Cancer Research, 2008, 68, 1953-1961.	0.9	435
3	Metastasis-Associated Gene Expression Changes Predict Poor Outcomes in Patients with Dukes Stage B and C Colorectal Cancer. Clinical Cancer Research, 2009, 15, 7642-7651.	7.0	395
4	Colorectal Cancer Cell Lines Are Representative Models of the Main Molecular Subtypes of Primary Cancer. Cancer Research, 2014, 74, 3238-3247.	0.9	317
5	A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nature Genetics, 2006, 38, 566-569.	21.4	254
6	Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. British Journal of Cancer, 2004, 91, 1931-1946.	6.4	212
7	HDAC4 Promotes Growth of Colon Cancer Cells via Repression of p21. Molecular Biology of the Cell, 2008, 19, 4062-4075.	2.1	188
8	SMAD4 as a Prognostic Marker in Colorectal Cancer. Clinical Cancer Research, 2005, 11, 2606-2611.	7.0	172
9	Gene expression profiling of intestinal epithelial cell maturation along the crypt-villus axis. Gastroenterology, 2005, 128, 1081-1088.	1.3	171
10	Gene expression profiling-based prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Research, 2003, 63, 8791-812.	0.9	154
11	Serrated carcinomas form a subclass of colorectal cancer with distinct molecular basis. Oncogene, 2007, 26, 312-320.	5.9	136
12	Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. Human Molecular Genetics, 2004, 13, 2303-2311.	2.9	127
13	Gene-Expression Profiling Predicts Recurrence in Dukes' C Colorectal Cancer. Gastroenterology, 2005, 129, 874-884.	1.3	119
14	Candidate driver genes in microsatelliteâ€unstable colorectal cancer. International Journal of Cancer, 2012, 130, 1558-1566.	5.1	99
15	Na+/monocarboxylate transport (SMCT) protein expression correlates with survival in colon cancer: Molecular characterization of SMCT. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 7270-7275.	7.1	98
16	Apoptotic Sensitivity of Colon Cancer Cells to Histone Deacetylase Inhibitors Is Mediated by an Sp1/Sp3-Activated Transcriptional Program Involving Immediate-Early Gene Induction. Cancer Research, 2010, 70, 609-620.	0.9	98
17	RHOA inactivation enhances Wnt signalling and promotes colorectal cancer. Nature Communications, 2014, 5, 5458.	12.8	95
18	A gene expression profile that defines colon cell maturation in vitro. Cancer Research, 2002, 62, 4791-804	0.9	93

#	Article	IF	CITATIONS
19	SMAD4 Levels and Response to 5-Fluorouracil in Colorectal Cancer. Clinical Cancer Research, 2005, 11, 6311-6316.	7.0	89
20	TR3/Nur77 in colon cancer cell apoptosis. Cancer Research, 2003, 63, 5401-7.	0.9	89
21	Mechanisms of Inactivation of the Receptor Tyrosine Kinase EPHB2 in Colorectal Tumors. Cancer Research, 2005, 65, 10170-10173.	0.9	84
22	EPHB4 and Survival of Colorectal Cancer Patients. Cancer Research, 2006, 66, 8943-8948.	0.9	80
23	Unregulated smooth-muscle myosin in human intestinal neoplasia. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 5513-5518.	7.1	77
24	Mutations in the Circadian Gene <i>CLOCK</i> in Colorectal Cancer. Molecular Cancer Research, 2010, 8, 952-960.	3.4	77
25	Expression of seleniumâ€binding protein 1 characterizes intestinal cell maturation and predicts survival for patients with colorectal cancer. Molecular Nutrition and Food Research, 2008, 52, 1289-1299.	3.3	75
26	c-Myc overexpression sensitises colon cancer cells to camptothecin-induced apoptosis. British Journal of Cancer, 2003, 89, 1757-1765.	6.4	71
27	Dual Targeting of Bromodomain and Extraterminal Domain Proteins, and WNT or MAPK Signaling, Inhibits c-MYC Expression and Proliferation of Colorectal Cancer Cells. Molecular Cancer Therapeutics, 2016, 15, 1217-1226.	4.1	71
28	Gene expression signatures for colorectal cancer microsatellite status and HNPCC. British Journal of Cancer, 2005, 92, 2240-2248.	6.4	70
29	Fluorescent CSC models evidence that targeted nanomedicines improve treatment sensitivity of breast and colon cancer stem cells. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 1883-1892.	3.3	69
30	Distinct expression profile in fumarate-hydratase-deficient uterine fibroids. Human Molecular Genetics, 2006, 15, 97-103.	2.9	67
31	Oncogenic Ki-Ras Inhibits the Expression of Interferon-responsive Genes through Inhibition of STAT1 and STAT2 Expression. Journal of Biological Chemistry, 2003, 278, 46278-46287.	3.4	61
32	Brush border Myosin Ia has tumor suppressor activity in the intestine. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 1530-1535.	7.1	60
33	The Receptor Tyrosine Kinase EPHB4 Has Tumor Suppressor Activities in Intestinal Tumorigenesis. Cancer Research, 2009, 69, 7430-7438.	0.9	58
34	The Intestinal Epithelial Cell Differentiation Marker Intestinal Alkaline Phosphatase (ALPi) Is Selectively Induced by Histone Deacetylase Inhibitors (HDACi) in Colon Cancer Cells in a Kruppel-like Factor 5 (KLF5)-dependent Manner. Journal of Biological Chemistry, 2014, 289, 25306-25316.	3.4	53
35	Myo5b knockout mice as a model of microvillus inclusion disease. Scientific Reports, 2015, 5, 12312.	3.3	52
36	Nanotechnology is an important strategy for combinational innovative chemo-immunotherapies against colorectal cancer. Journal of Controlled Release, 2019, 307, 108-138.	9.9	49

#	Article	IF	CITATIONS
37	Novel detection and differential utilization of a c-myc transcriptional block in colon cancer chemoprevention. Cancer Research, 2002, 62, 6006-10.	0.9	47
38	Zileutonâ,,¢ loaded in polymer micelles effectively reduce breast cancer circulating tumor cells and intratumoral cancer stem cells. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 24, 102106.	3.3	44
39	PVT1 Long Non-coding RNA in Gastrointestinal Cancer. Frontiers in Oncology, 2020, 10, 38.	2.8	43
40	Human SMC2 Protein, a Core Subunit of Human Condensin Complex, Is a Novel Transcriptional Target of the WNT Signaling Pathway and a New Therapeutic Target. Journal of Biological Chemistry, 2012, 287, 43472-43481.	3.4	39
41	High EPHB2 mutation rate in gastric but not endometrial tumors with microsatellite instability. Oncogene, 2007, 26, 308-311.	5.9	38
42	EPH receptors in cancer. Histology and Histopathology, 2008, 23, 1011-23.	0.7	37
43	Aprataxin Tumor Levels Predict Response of Colorectal Cancer Patients to Irinotecan-based Treatment. Clinical Cancer Research, 2010, 16, 2375-2382.	7.0	35
44	Polymeric micelles targeted against CD44v6 receptor increase niclosamide efficacy against colorectal cancer stem cells and reduce circulating tumor cells in vivo. Journal of Controlled Release, 2021, 331, 198-212.	9.9	35
45	An A13 Repeat within the 3′-Untranslated Region of Epidermal Growth Factor Receptor (EGFR) Is Frequently Mutated in Microsatellite Instability Colon Cancers and Is Associated with Increased EGFR Expression. Cancer Research, 2009, 69, 7811-7818.	0.9	34
46	7q deletion mapping and expression profiling in uterine fibroids. Oncogene, 2005, 24, 6545-6554.	5.9	33
47	Transforming pathways unleashed by a HDAC2 mutation in human cancer. Oncogene, 2008, 27, 4008-4012.	5.9	33
48	AKT2 siRNA delivery with amphiphilic-based polymeric micelles show efficacy against cancer stem cells. Drug Delivery, 2018, 25, 961-972.	5.7	32
49	Pivotal Role of AKT2 during Dynamic Phenotypic Change of Breast Cancer Stem Cells. Cancers, 2019, 11, 1058.	3.7	32
50	A Molecular Mechanism Underlying Genotypeâ€ s pecific Intrahepatic Cholestasis Resulting From MYO5B Mutations. Hepatology, 2020, 72, 213-229.	7.3	30
51	Villin Expression Is Frequently Lost in Poorly Differentiated Colon Cancer. American Journal of Pathology, 2012, 180, 1509-1521.	3.8	28
52	Cancer stem cells and personalized cancer nanomedicine. Nanomedicine, 2016, 11, 307-320.	3.3	27
53	Efficient EFGR mediated siRNA delivery to breast cancer cells by Cetuximab functionalized Pluronic® F127/Gelatin. Chemical Engineering Journal, 2018, 340, 81-93.	12.7	26
54	Tumour selection advantage of non-dominant negative P53 mutations in homozygotic MDM2-SNP309 colorectal cancer cells. Journal of Medical Genetics, 2006, 44, 75-80.	3.2	25

#	Article	IF	CITATIONS
55	Highly Expressed Genes in Rapidly Proliferating Tumor Cells as New Targets for Colorectal Cancer Treatment. Clinical Cancer Research, 2015, 21, 3695-3704.	7.0	25
56	Loss of the EPH receptor B6 contributes to colorectal cancer metastasis. Scientific Reports, 2017, 7, 43702.	3.3	25
57	Mechanisms of inactivation of the tumour suppressor gene RHOA in colorectal cancer. British Journal of Cancer, 2018, 118, 106-116.	6.4	24
58	Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia–Related Head and Neck Cancer. Clinical Cancer Research, 2020, 26, 3044-3057.	7.0	23
59	Decrease in c-Myc activity enhances cancer cell sensitivity to vinblastine. Anti-Cancer Drugs, 2006, 17, 181-187.	1.4	21
60	Brush border myosin la inactivation in gastric but not endometrial tumors. International Journal of Cancer, 2013, 132, 1790-1799.	5.1	21
61	Diagnostic ultrasound induces change within numbers of cryptal mitotic and apoptotic cells in small intestine. Life Sciences, 2001, 68, 1471-1475.	4.3	20
62	Tumor Expression of Cyclin-Dependent Kinase 5 (Cdk5) Is a Prognostic Biomarker and Predicts Outcome of Oxaliplatin-Treated Metastatic Colorectal Cancer Patients. Cancers, 2019, 11, 1540.	3.7	19
63	Microarray analysis in the clinical management of cancer. Hematology/Oncology Clinics of North America, 2003, 17, 377-387.	2.2	18
64	Dynamism, Sensitivity, and Consequences of Mesenchymal and Stem-Like Phenotype of Cancer Cells. Stem Cells International, 2018, 2018, 1-12.	2.5	17
65	Mutations in Two Short Noncoding Mononucleotide Repeats in Most Microsatellite-Unstable Colorectal Cancers. Cancer Research, 2005, 65, 4607-4613.	0.9	16
66	Intracellular Delivery of Anti-SMC2 Antibodies against Cancer Stem Cells. Pharmaceutics, 2020, 12, 185.	4.5	16
67	Customizing chemotherapy for colon cancer: the potential of gene expression profiling. Drug Resistance Updates, 2004, 7, 209-218.	14.4	15
68	Germline hypermethylation of the <i>APC</i> promoter is not a frequent cause of familial adenomatous polyposis in <i>APC/MUTYH</i> mutation negative families. International Journal of Cancer, 2008, 122, 1422-1425.	5.1	15
69	Application of Gene Expression Profiling to Colon Cell Maturation, Transformation and Chemoprevention. Journal of Nutrition, 2003, 133, 2410S-2416S.	2.9	14
70	<i>PTPRD</i> is Homozygously Deleted and Epigenetically Downregulated in Human Hepatocellular Carcinomas. OMICS A Journal of Integrative Biology, 2015, 19, 220-229.	2.0	14
71	BB-10010, an analog of macrophage inflammatory protein-1alpha, protects murine small intestine against radiation. Digestive Diseases and Sciences, 2001, 46, 2608-2614.	2.3	13
72	Tumor necrosis factor-α related gene response to Epothilone B in ovarian cancer. Gynecologic Oncology, 2004, 93, 19-26.	1.4	12

#	Article	IF	CITATIONS
73	Silencing of adaptor protein <scp>SH</scp> 3 <scp>BP</scp> 2 reduces <scp>KIT</scp> / <scp>PDGFRA</scp> receptors expression and impairs gastrointestinal stromal tumors growth. Molecular Oncology, 2018, 12, 1383-1397.	4.6	12
74	DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis. Scientific Reports, 2018, 8, 1767.	3.3	11
75	Glucocorticoids and myosin5b loss of function induce heightened PKA signaling in addition to membrane traffic defects. Molecular Biology of the Cell, 2019, 30, 3076-3089.	2.1	11
76	Loss of MYO5B expression deregulates late endosome size which hinders mitotic spindle orientation. PLoS Biology, 2019, 17, e3000531.	5.6	10
77	Investigation of the role of tyrosine kinase receptor EPHA3 in colorectal cancer. Scientific Reports, 2017, 7, 41576.	3.3	9
78	BB-10010, an Analogue of Macrophage Inflammatory Protein-1 Alpha, Reduces Proliferation in Murine Small-Intestinal Crypts. Scandinavian Journal of Gastroenterology, 1999, 34, 68-72.	1.5	8
79	Modeling tumor predisposingFHmutations in yeast: Effects on fumarase activity, growth phenotype and gene expression profile. International Journal of Cancer, 2006, 118, 1340-1345.	5.1	7
80	Rational Design of a siRNA Delivery System: ALOX5 and Cancer Stem Cells as Therapeutic Targets. Precision Nanomedicine, 2018, 1, 86-105.	0.8	6
81	Epithelial de-differentiation triggered by co-ordinate epigenetic inactivation of the EHF and CDX1 transcription factors drives colorectal cancer progression. Cell Death and Differentiation, 2022, 29, 2288-2302.	11.2	6
82	Identification of ZBTB18 as a novel colorectal tumor suppressor gene through genome-wide promoter hypermethylation analysis. Clinical Epigenetics, 2021, 13, 88.	4.1	5
83	Correction: Prediction of Response to Cetuximab. Cancer Research, 2008, 68, 6859-6859.	0.9	4
84	Clinical Response to Fluorouracil andp53. New England Journal of Medicine, 2001, 345, 1065-1066.	27.0	3
85	Colorectal cancer inhibition by BET inhibitor JQ1 is MYC-independent and not improved by nanoencapsulation. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 171, 39-49.	4.3	3
86	Dose-effect relationship of BB-10010/MIP-1 alpha on proliferation in murine small intestinal epithelium: single and double administration protocols. Digestive Diseases and Sciences, 2000, 45, 2306-2312.	2.3	2
87	Dickkopf-1 Inhibition Reactivates Wnt/β-Catenin Signaling in Rhabdomyosarcoma, Induces Myogenic Markers In Vitro and Impairs Tumor Cell Survival In Vivo. International Journal of Molecular Sciences, 2021, 22, 12921.	4.1	2
88	Cell-cycle perturbations following low-dose x-rays. Radiography, 1999, 5, 111-115.	2.1	0
89	Reply to the Letter to the Editor by Watanabe et al Clinical Cancer Research, 2006, 12, 1654.1-1655.	7.0	Ο
90	Correction: An A13 Repeat within the 3′-Untranslated Region of Epidermal Growth Factor Receptor (EGFR) Is Frequently Mutated in Microsatellite Instability Colon Cancers and Is Associated with Increased EGFR Expression. Cancer Research, 2010, 70, 1275-1275.	0.9	0

#	Article	IF	CITATIONS
91	Abstract 4921: Selective promoter methylation of the cell differentiation marker, intestinal alkaline phosphatase (iALP), in microsatellite unstable colon cancer. , 2010, , .		Ο
92	Eph Receptors. , 2011, , 1268-1269.		0
93	Abstract 4316: Villin expression is frequently lost in colon cancers with microsatellite instability , 2012, , .		Ο
94	Abstract 5172: Whole exome mutation landscape of 70 commonly used colorectal cancer cell lines. , 2014, , .		0
95	Eph Receptors. , 2015, , 1549-1551.		Ο
96	Abstract 2058: RHOA inactivation enhances Wnt signaling and promotes colorectal cancer. , 2015, , .		0
97	Abstract 840: Identification of novel colorectal tumor suppressor genes through genome-wide promoter hypermethylation analysis. , 2019, , .		ο